Shared on 14 Aug 26

Fair value Decreased 27%

CLBT: Federal AI And Cloud Demand Will Support Premium Future P/E Potential

Cellebrite faces a tougher near-term picture as sales take longer to close and growth expectations cool, while a sudden leadership change adds uncertainty. Even so, some analysts still see long-run demand for its digital investigation tools holding up, helped by new partnerships and customer needs.

6 views

Shared on 04 Jun 26

Fair value Decreased 3.08%

CLBT: Federal AI And Cloud Adoption Will Support Premium P/E Potential

Cellebrite says its U.S. federal business is picking back up, helped by new AI tools and a newly cleared government cloud that could open doors across more agencies. But even with solid progress, some analysts warn the stock can still get cheaper if the market cools on tech valuations.

11 views

Shared on 22 Apr 26

CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential

Analysts have trimmed their price targets on Cellebrite DI by $2. This reflects updated views on the stock's risk profile and valuation assumptions, while core growth and margin expectations remain largely unchanged.

9 views

Shared on 07 Apr 26

CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential

Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event.

8 views

Shared on 24 Mar 26

CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential

Analysts trimmed their price targets for Cellebrite DI by $2 to $21.67, citing updated assumptions on discount rate, long term revenue growth, profit margin and future P/E. These changes keep fair value broadly unchanged while slightly adjusting the risk and return profile.

11 views

Shared on 09 Mar 26

CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration

Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged. Analyst Commentary Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions.

10 views

Shared on 23 Feb 26

Fair value Decreased 12%

CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power

Analysts have adjusted their average price target on Cellebrite DI to about $21.67, down from the previous $24.71 level. The revised target reflects updated views on fair value, profit margins and future P/E assumptions following recent research updates from multiple firms.

7 views

Shared on 25 Jan 26

CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power

Analysts have maintained their price target on Cellebrite DI at US$24.71, with only minor tweaks to inputs such as the discount rate and forward P/E, reflecting stable expectations around revenue growth and profit margin assumptions. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, targeting revenue of US$123 million to US$128 million, with annual growth of 13% to 17% (company guidance).

9 views

Shared on 10 Jan 26

CLBT: Sustained Margin Strength Will Support Future Earnings Power

Analysts have maintained their fair value estimate for Cellebrite DI at US$24.71, making only minor adjustments to inputs such as the discount rate and long term P/E assumptions. This reflects a view that recent information does not materially alter their price outlook.

7 views

Shared on 24 Dec 25

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, citing incremental improvements in the company’s discount rate assumptions and sustained expectations for high revenue growth and robust profit margins. What's in the News Cellebrite DI issued fourth quarter 2025 revenue guidance of $123 million to $128 million, implying year over year growth of 13% to 17% (company guidance).

9 views

Shared on 10 Dec 25

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).

12 views

Shared on 26 Nov 25

Fair value Increased 6.79%

CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year

Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.

7 views

Shared on 23 Sep 25

Fair value Increased 2.53%

Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.

29 views

Shared on 15 Aug 25

Fair value Decreased 1.86%

Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.

8 views

Shared on 01 May 25

Fair value Decreased 5.29%

0 views

Cloud SaaS Solutions Will Drive Digital Forensics Adoption

CLBT: Federal AI And Cloud Demand Will Support Premium Future P/E Potential

CLBT: Federal AI And Cloud Adoption Will Support Premium P/E Potential

CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential

CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential

CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential

CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration

CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power

CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power

CLBT: Sustained Margin Strength Will Support Future Earnings Power

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year

Shared on 23 Sep 25

Shared on 15 Aug 25

Shared on 01 May 25

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on Cellebrite DI

Company analysis

CEO & management